You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCabazitaxel
Accession NumberDB06772
TypeSmall Molecule
GroupsApproved
DescriptionCabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.
Structure
Thumb
Synonyms
Cabazitaxelum
Taxoid XRP6258
TXD258
XRP6258
External Identifiers
  • RPR-116258A
  • RPR116258
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JevtanakitSanofi Aventis U.S. Llc2010-06-17Not applicableUs
Jevtanasolution40 mgintravenousSanofi Aventis Canada Inc2011-08-23Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII51F690397J
CAS number183133-96-2
WeightAverage: 835.9324
Monoisotopic: 835.377905537
Chemical FormulaC45H57NO14
InChI KeyInChIKey=BMQGVNUXMIRLCK-OAGWZNDDSA-N
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@@](O)([C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • Phenylpropylamine
  • Benzoate ester
  • Tricarboxylic acid or derivatives
  • Benzylether
  • Benzoic acid or derivatives
  • Benzoyl
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Monosaccharide
  • Monocyclic benzene moiety
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • Oxetane
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
PharmacodynamicsCabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours.
Mechanism of actionCabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.
Related Articles
AbsorptionAfter an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel.
Volume of distribution

The volume of distribution (Vss) was 4,864 L (2,643 L/m2 for a patient with a median BSA of 1.84 m2) at steady state. Compared to other taxanes, penetrates the CNS to a greater extent.

Protein bindingCabazitaxel is mainly bound to human serum albumin (82%) and lipoproteins (88% for HDL, 70% for LDL, and 56% for VLDL).
Metabolism

Cabazitaxel is extensively metabolized in the liver (>95%), mainly by the CYP3A4/5 isoenzyme (80% to 90%), and to a lesser extent by CYP2C8 which results in 20 different metabolites. Two of these metabolites are active demethylated derivatives of cabaxitaxel and referred to as RPR112698 and RPR123142 respectively. Docetaxel is another metabolite of cabazitaxel. Cabazitaxel is the main circulating moiety in human plasma.

SubstrateEnzymesProduct
Cabazitaxel
Not Available
DocetaxelDetails
Cabazitaxel
Not Available
RPR112698Details
Cabazitaxel
Not Available
RPR123142Details
Route of eliminationAfter a one-hour intravenous infusion [14C]-cabazitaxel 25 mg/m2, approximately 80% of the administered dose was eliminated within 2 weeks. Cabazitaxel is mainly excreted in the feces as numerous metabolites (76% of the dose); while renal excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as unchanged drug in urine).
Half lifeFollowing a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.
Clearance

Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer.

ToxicityCabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and renal failure. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Cabazitaxel penetrates the blood-brain barrier. LD50, rat = 500 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier-0.9825
Caco-2 permeable-0.7945
P-glycoprotein substrateSubstrate0.8287
P-glycoprotein inhibitor IInhibitor0.6646
P-glycoprotein inhibitor IIInhibitor0.5887
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.8236
CYP450 2D6 substrateNon-substrate0.882
CYP450 3A4 substrateSubstrate0.7256
CYP450 1A2 substrateNon-inhibitor0.8197
CYP450 2C9 inhibitorNon-inhibitor0.8654
CYP450 2D6 inhibitorNon-inhibitor0.8935
CYP450 2C19 inhibitorNon-inhibitor0.8429
CYP450 3A4 inhibitorNon-inhibitor0.6339
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.8028
CarcinogenicityNon-carcinogens0.9264
BiodegradationNot ready biodegradable0.9926
Rat acute toxicity2.6378 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7906
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
Solutionintravenous40 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5438072 No2010-06-172013-11-22Us
US5698582 No2010-06-172012-07-03Us
US5847170 No2001-03-262021-03-26Us
US6331635 No1996-03-262016-03-26Us
US6372780 No1996-03-262016-03-26Us
US6387946 No1996-03-262016-03-26Us
US7241907 No2005-12-102025-12-10Us
US8927592 No2010-10-272030-10-27Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.69ALOGPS
logP4.2ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.97ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area202.45 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity213.4 m3·mol-1ChemAxon
Polarizability86.39 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Nagesh Palepu, “CABAZITAXEL FORMULATIONS AND METHODS OF PREPARING THEREOF.” U.S. Patent US20120065255, issued March 15, 2012.

US20120065255
General References
  1. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK: Cabazitaxel. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. [PubMed:20811375 ]
  2. Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH: Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:117-23. doi: 10.1016/j.jchromb.2013.02.034. Epub 2013 Mar 5. [PubMed:23542607 ]
  3. Nightingale G, Ryu J: Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012 Aug;37(8):440-8. [PubMed:23091336 ]
External Links
ATC CodesL01CD04
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (383 KB)
MSDSDownload (99.2 KB)
Interactions
Drug Interactions
Drug
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-Methoxyestradiol.
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3-Methoxybenzamide.
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3,4-Dihydroxybenzoic Acid.
5,10-Dideazatetrahydrofolic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 7-Hydroxystaurosporine.
8-azaguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneThe serum concentration of Cabazitaxel can be increased when it is combined with Abiraterone.
AbirateroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Abiraterone.
ABT-263The risk or severity of adverse effects can be increased when Cabazitaxel is combined with ABT-263.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Cabazitaxel.
AcetaminophenThe serum concentration of Cabazitaxel can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cabazitaxel.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Cabazitaxel.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cabazitaxel.
AfimoxifeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Afimoxifene.
AfliberceptThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aflibercept.
AlatrofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alatrofloxacin.
AlbendazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Albendazole.
AlbendazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.
AldosteroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Cabazitaxel.
AlectinibThe serum concentration of Cabazitaxel can be increased when it is combined with Alectinib.
AlemtuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alemtuzumab.
AlfentanilThe serum concentration of Cabazitaxel can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Cabazitaxel.
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alpha-Difluoromethylornithine.
AltretamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Altretamine.
AmantadineThe serum concentration of Cabazitaxel can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cabazitaxel.
AminoglutethimideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminoglutethimide.
Aminohippuric acidThe serum concentration of Cabazitaxel can be increased when it is combined with Aminohippuric acid.
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminolevulinic acid.
AmiodaroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Cabazitaxel can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Cabazitaxel can be increased when it is combined with Amlodipine.
AmonafideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amonafide.
AmprenavirThe serum concentration of Cabazitaxel can be decreased when it is combined with Amprenavir.
AmrubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amrubicin.
AmsacrineThe serum concentration of Cabazitaxel can be increased when it is combined with Amsacrine.
AmsacrineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amsacrine.
AnagrelideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anagrelide.
AnastrozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anastrozole.
annamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with annamycin.
AP 12009The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AP 12009.
AP24534The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AP24534.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cabazitaxel.
AprepitantThe serum concentration of Cabazitaxel can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Cabazitaxel.
ASA404The risk or severity of adverse effects can be increased when Cabazitaxel is combined with ASA404.
AsparaginaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Asparaginase.
AstemizoleThe serum concentration of Cabazitaxel can be increased when it is combined with Astemizole.
AT-101The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AT-101.
AtazanavirThe serum concentration of Cabazitaxel can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Cabazitaxel can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Cabazitaxel can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Cabazitaxel can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Cabazitaxel.
AzacitidineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azacitidine.
AzathioprineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azathioprine.
AZD2171The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AZD2171.
Azelaic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azelaic Acid.
AzelastineThe serum concentration of Cabazitaxel can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Azithromycin.
BatimastatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Batimastat.
BelinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Belinostat.
BendamustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bendamustine.
BenzocaineThe serum concentration of Cabazitaxel can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Cabazitaxel can be increased when it is combined with Bepridil.
BesifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Besifloxacin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cabazitaxel.
BevacizumabBevacizumab may increase the cardiotoxic activities of Cabazitaxel.
BevacizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bevacizumab.
BexaroteneThe serum concentration of Cabazitaxel can be decreased when it is combined with Bexarotene.
BexaroteneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bexarotene.
BicalutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bicalutamide.
BiperidenThe serum concentration of Cabazitaxel can be increased when it is combined with Biperiden.
BleomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bleomycin.
BlinatumomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Blinatumomab.
BoceprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Cabazitaxel can be decreased when combined with Bortezomib.
BortezomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bortezomib.
BosentanThe serum concentration of Cabazitaxel can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cabazitaxel.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cabazitaxel.
BromocriptineThe serum concentration of Cabazitaxel can be increased when it is combined with Bromocriptine.
BSI-201The risk or severity of adverse effects can be increased when Cabazitaxel is combined with BSI-201.
BuprenorphineThe serum concentration of Cabazitaxel can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Cabazitaxel can be increased when it is combined with Buspirone.
BusulfanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Busulfan.
CabergolineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabergoline.
CabozantinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabozantinib.
CaffeineThe serum concentration of Cabazitaxel can be increased when it is combined with Caffeine.
CalcipotriolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Calcipotriol.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Cabazitaxel.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Cabazitaxel.
CandesartanThe serum concentration of Cabazitaxel can be increased when it is combined with Candesartan.
CapecitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Capecitabine.
CaptoprilThe serum concentration of Cabazitaxel can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Cabazitaxel can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cabazitaxel.
CarboplatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carboplatin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Cabazitaxel.
CarmofurThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carmofur.
CarmustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carmustine.
CarvedilolThe serum concentration of Cabazitaxel can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Cabazitaxel can be increased when it is combined with Caspofungin.
CatumaxomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Catumaxomab.
CB1954The risk or severity of adverse effects can be increased when Cabazitaxel is combined with CB1954.
CelecoxibThe metabolism of Cabazitaxel can be decreased when combined with Celecoxib.
CelecoxibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Celecoxib.
CeritinibThe serum concentration of Cabazitaxel can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cabazitaxel.
CetuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.
ChlorambucilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorambucil.
ChloroquineThe serum concentration of Cabazitaxel can be increased when it is combined with Chloroquine.
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorotrianisene.
ChlorpromazineThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Cabazitaxel can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Cabazitaxel can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Cabazitaxel can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Cabazitaxel can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cabazitaxel.
CinoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cinoxacin.
CiprofloxacinThe serum concentration of Cabazitaxel can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Cabazitaxel.
CitalopramThe serum concentration of Cabazitaxel can be increased when it is combined with Citalopram.
CladribineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cladribine.
ClarithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Cabazitaxel can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cabazitaxel.
ClofarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clofarabine.
ClofazimineThe serum concentration of Cabazitaxel can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cabazitaxel.
ClomipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Cabazitaxel.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Cabazitaxel.
ClopidogrelThe metabolism of Cabazitaxel can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Cabazitaxel can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clozapine.
CobicistatThe serum concentration of Cabazitaxel can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cabazitaxel.
ColchicineThe serum concentration of Cabazitaxel can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Cabazitaxel can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Cabazitaxel can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cabazitaxel.
CrizotinibThe metabolism of Cabazitaxel can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Cabazitaxel.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cabazitaxel.
CyclophosphamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cyclophosphamide.
CyclosporineThe metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Cabazitaxel.
Cyproterone acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cyproterone acetate.
CytarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cytarabine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Cabazitaxel.
DabrafenibThe serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Cabazitaxel.
DacarbazineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dacarbazine.
DaclatasvirThe serum concentration of Cabazitaxel can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Cabazitaxel can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Cabazitaxel.
DaratumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Daratumumab.
DarunavirThe serum concentration of Cabazitaxel can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Cabazitaxel can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Cabazitaxel.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cabazitaxel.
DecitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine.
DeferasiroxThe serum concentration of Cabazitaxel can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Cabazitaxel can be decreased when combined with Delavirdine.
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Denileukin diftitox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cabazitaxel.
DesipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cabazitaxel.
DesloratadineThe serum concentration of Cabazitaxel can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Cabazitaxel can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Cabazitaxel.
DexrazoxaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexrazoxane.
DextromethorphanThe serum concentration of Cabazitaxel can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cabazitaxel.
DiclofenacThe serum concentration of Cabazitaxel can be increased when it is combined with Diclofenac.
DienogestThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dienogest.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cabazitaxel.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cabazitaxel.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Cabazitaxel.
DigoxinDigoxin may decrease the cardiotoxic activities of Cabazitaxel.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cabazitaxel.
DihydroergotamineThe metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cabazitaxel.
DiltiazemThe metabolism of Cabazitaxel can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cabazitaxel.
DinutuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.
DipyridamoleThe serum concentration of Cabazitaxel can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Cabazitaxel.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cabazitaxel.
DoxazosinThe serum concentration of Cabazitaxel can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Cabazitaxel can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Cabazitaxel can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cabazitaxel.
DoxycyclineThe metabolism of Cabazitaxel can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Cabazitaxel can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Cabazitaxel can be decreased when combined with Dronedarone.
EcabetThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ecabet.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cabazitaxel.
efaproxiralThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with efaproxiral.
EfavirenzThe serum concentration of Cabazitaxel can be decreased when it is combined with Efavirenz.
EflornithineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eflornithine.
EG009The risk or severity of adverse effects can be increased when Cabazitaxel is combined with EG009.
ElbasvirThe serum concentration of Cabazitaxel can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cabazitaxel.
ElsamitrucinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Elsamitrucin.
EnalaprilThe serum concentration of Cabazitaxel can be increased when it is combined with Enalapril.
EndostatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Endostatin.
EnoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enoxacin.
EnrofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enrofloxacin.
EnzalutamideThe serum concentration of Cabazitaxel can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cabazitaxel.
EpirubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epirubicin.
Epothilone BThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epothilone B.
ErgonovineThe serum concentration of Cabazitaxel can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Cabazitaxel can be increased when it is combined with Ergotamine.
EribulinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Cabazitaxel.
ErythromycinThe metabolism of Cabazitaxel can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Cabazitaxel.
Eslicarbazepine acetateThe serum concentration of Cabazitaxel can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cabazitaxel.
EstramustineThe serum concentration of Cabazitaxel can be increased when it is combined with Estramustine.
EstramustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Estramustine.
EstriolThe serum concentration of Cabazitaxel can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Cabazitaxel.
EstroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Cabazitaxel.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cabazitaxel.
Ethiodized oilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethiodized oil.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate.
EtoposideThe serum concentration of Cabazitaxel can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Cabazitaxel can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.
ExemestaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exemestane.
exisulindThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cabazitaxel.
FelodipineThe serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.
FenretinideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fenretinide.
FentanylThe serum concentration of Cabazitaxel can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cabazitaxel.
FexofenadineThe serum concentration of Cabazitaxel can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cabazitaxel.
FingolimodCabazitaxel may increase the immunosuppressive activities of Fingolimod.
FlavopiridolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flavopiridol.
FleroxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fleroxacin.
FloxuridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Floxuridine.
FluconazoleThe metabolism of Cabazitaxel can be decreased when combined with Fluconazole.
FludarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fludarabine.
FlumequineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flumequine.
FluorouracilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fluorouracil.
FluoxetineThe serum concentration of Cabazitaxel can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Cabazitaxel can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Cabazitaxel can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Cabazitaxel can be increased when it is combined with Flurazepam.
FlutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flutamide.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cabazitaxel.
FluvoxamineThe metabolism of Cabazitaxel can be decreased when combined with Fluvoxamine.
FormestaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formestane.
FormycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formycin.
FosamprenavirThe metabolism of Cabazitaxel can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Cabazitaxel can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Cabazitaxel can be increased when combined with Fosphenytoin.
FotemustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fotemustine.
FulvestrantThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fulvestrant.
FumagillinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fumagillin.
Fusidic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Fusidic Acid.
Gallium nitrateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gallium nitrate.
GarenoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Garenoxacin.
GatifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gatifloxacin.
GefitinibThe serum concentration of Cabazitaxel can be increased when it is combined with Gefitinib.
GeldanamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Cabazitaxel.
GemfibrozilThe metabolism of Cabazitaxel can be decreased when combined with Gemfibrozil.
GemifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemifloxacin.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemtuzumab ozogamicin.
GenisteinThe serum concentration of Cabazitaxel can be increased when it is combined with Genistein.
GenisteinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Genistein.
Ginsenoside CThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ginsenoside C.
GlyburideThe serum concentration of Cabazitaxel can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Cabazitaxel can be increased when it is combined with Glycerol.
GoserelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Goserelin.
Gramicidin DThe serum concentration of Cabazitaxel can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cabazitaxel.
GrepafloxacinThe serum concentration of Cabazitaxel can be increased when it is combined with Grepafloxacin.
HadacidinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hadacidin.
HalofuginoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Halofuginone.
HaloperidolThe serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol.
HexestrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hexestrol.
HydrocortisoneThe serum concentration of Cabazitaxel can be increased when it is combined with Hydrocortisone.
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyprogesterone caproate.
HydroxyureaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyurea.
IbrutinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ibrutinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Cabazitaxel.
IdarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idarubicin.
IdelalisibThe serum concentration of Cabazitaxel can be increased when it is combined with Idelalisib.
IfosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ifosfamide.
ImatinibThe metabolism of Cabazitaxel can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Cabazitaxel.
ImipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Imipramine.
ImiquimodThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Imiquimod.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cabazitaxel.
IndinavirThe serum concentration of Cabazitaxel can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Cabazitaxel.
IndomethacinThe serum concentration of Cabazitaxel can be increased when it is combined with Indomethacin.
Interferon beta-1aThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1a.
IobenguaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Iobenguane.
IpilimumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ipilimumab.
IrbesartanThe metabolism of Cabazitaxel can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Cabazitaxel.
IsavuconazoniumThe metabolism of Cabazitaxel can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Cabazitaxel can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Cabazitaxel can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Cabazitaxel can be increased when it is combined with Ivermectin.
IxabepiloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixabepilone.
IxazomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixazomib.
KetamineThe serum concentration of Cabazitaxel can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cabazitaxel.
KetoconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Ketoconazole.
KOS-1584The risk or severity of adverse effects can be increased when Cabazitaxel is combined with KOS-1584.
L-alanosineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with L-alanosine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cabazitaxel.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cabazitaxel.
LanreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lanreotide.
LansoprazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Cabazitaxel can be increased when it is combined with Lapatinib.
LapatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cabazitaxel.
LeflunomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Cabazitaxel.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Cabazitaxel.
LetrozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Letrozole.
LeuprolideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cabazitaxel.
LevofloxacinThe serum concentration of Cabazitaxel can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cabazitaxel.
LevothyroxineThe serum concentration of Cabazitaxel can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Cabazitaxel can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Cabazitaxel.
LiothyronineThe serum concentration of Cabazitaxel can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Cabazitaxel can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Cabazitaxel can be increased when it is combined with Lisinopril.
LomefloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomefloxacin.
LomitapideThe serum concentration of Cabazitaxel can be increased when it is combined with Lomitapide.
LomustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomustine.
LonidamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lonidamine.
LoperamideThe serum concentration of Cabazitaxel can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Cabazitaxel can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Cabazitaxel can be increased when it is combined with Losartan.
LovastatinThe metabolism of Cabazitaxel can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Cabazitaxel can be decreased when it is combined with Lumacaftor.
LycopeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lycopene.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Cabazitaxel.
MaprotilineThe serum concentration of Cabazitaxel can be increased when it is combined with Maprotiline.
MasitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masitinib.
MasoprocolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masoprocol.
MaxacalcitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Maxacalcitol.
MDX-1106The risk or severity of adverse effects can be increased when Cabazitaxel is combined with MDX-1106.
MebendazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Mebendazole.
MebendazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mebendazole.
MechlorethamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mechlorethamine.
MedrogestoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medrogestone.
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medroxyprogesterone acetate.
MefloquineThe serum concentration of Cabazitaxel can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Cabazitaxel can be increased when it is combined with Megestrol acetate.
Megestrol acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Megestrol acetate.
MelphalanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Melphalan.
MeprobamateThe serum concentration of Cabazitaxel can be increased when it is combined with Meprobamate.
MequinolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mequinol.
MercaptopurineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mercaptopurine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cabazitaxel.
MethadoneThe serum concentration of Cabazitaxel can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cabazitaxel.
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyl aminolevulinate.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cabazitaxel.
MethyltestosteroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyltestosterone.
MetoprololThe serum concentration of Cabazitaxel can be increased when it is combined with Metoprolol.
MGI-114The risk or severity of adverse effects can be increased when Cabazitaxel is combined with MGI-114.
MibefradilThe serum concentration of Cabazitaxel can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cabazitaxel.
MidostaurinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Midostaurin.
MifepristoneThe metabolism of Cabazitaxel can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Miltefosine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cabazitaxel.
MitomycinThe serum concentration of Cabazitaxel can be increased when it is combined with Mitomycin.
MitomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitomycin.
MitotaneThe serum concentration of Cabazitaxel can be decreased when it is combined with Mitotane.
MitotaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitotane.
MitoxantroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cabazitaxel.
ModafinilThe serum concentration of Cabazitaxel can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Cabazitaxel can be increased when it is combined with Morphine.
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with motexafin gadolinium.
MoxifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cabazitaxel.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.
NadololThe serum concentration of Nadolol can be increased when it is combined with Cabazitaxel.
NafcillinThe serum concentration of Cabazitaxel can be decreased when it is combined with Nafcillin.
Nalidixic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nalidixic Acid.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cabazitaxel.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cabazitaxel.
NaltrexoneThe serum concentration of Cabazitaxel can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Cabazitaxel can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.
NecitumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Necitumumab.
NefazodoneThe serum concentration of Cabazitaxel can be decreased when it is combined with Nefazodone.
NelarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nelarabine.
NelfinavirThe serum concentration of Cabazitaxel can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Cabazitaxel.
NeostigmineThe serum concentration of Cabazitaxel can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Cabazitaxel can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Cabazitaxel can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Cabazitaxel can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Cabazitaxel can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cabazitaxel.
NiguldipineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.
NilotinibThe metabolism of Cabazitaxel can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Cabazitaxel.
NilutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilutamide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cabazitaxel.
NisoldipineThe serum concentration of Cabazitaxel can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine.
NivolumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nivolumab.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cabazitaxel.
nocodazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with nocodazole.
NorethisteroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Norethisterone.
NorfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Norfloxacin.
ObinutuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab.
OctreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Octreotide.
OfatumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofatumumab.
OfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cabazitaxel.
OlaparibThe metabolism of Cabazitaxel can be decreased when combined with Olaparib.
OlaparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Olaparib.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Omacetaxine mepesuccinate.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cabazitaxel.
OmeprazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Omeprazole.
OprelvekinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.
OsimertinibThe serum concentration of Cabazitaxel can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Cabazitaxel.
OxaliplatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oxaliplatin.
P-NitrophenolThe serum concentration of Cabazitaxel can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib.
PalbociclibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Palbociclib.
PalifosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Palifosfamide.
Palmitic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Palmitic Acid.
PamidronateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pamidronate.
PanitumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panitumumab.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Cabazitaxel.
PantoprazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Cabazitaxel can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.
PefloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pefloxacin.
PegaspargaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegaspargase.
PembrolizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pembrolizumab.
PemetrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.
PentobarbitalThe metabolism of Cabazitaxel can be increased when combined with Pentobarbital.
PentostatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pentostatin.
PerindoprilThe serum concentration of Cabazitaxel can be increased when it is combined with Perindopril.
PertuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pertuzumab.
PhenobarbitalThe serum concentration of Cabazitaxel can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Cabazitaxel.
Phenylacetic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Phenylacetic acid.
PhenytoinThe metabolism of Cabazitaxel can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cabazitaxel.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel.
PimozideThe serum concentration of Cabazitaxel can be increased when it is combined with Pimozide.
PioglitazoneThe metabolism of Cabazitaxel can be decreased when combined with Pioglitazone.
PipobromanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pipobroman.
PirfenidoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirfenidone.
PirlindoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cabazitaxel.
PixantroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pixantrone.
Platelet Activating FactorThe serum concentration of Cabazitaxel can be decreased when it is combined with Platelet Activating Factor.
PlicamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Plicamycin.
PodofiloxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Podofilox.
PodophyllinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Podophyllin.
polyacrylic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with polyacrylic acid.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Cabazitaxel.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Cabazitaxel.
PorfimerThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Porfimer.
porfiromycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with porfiromycin.
PosaconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Posaconazole.
PralatrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pralatrexate.
PravastatinThe serum concentration of Cabazitaxel can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Cabazitaxel can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Cabazitaxel.
PrednisoneThe serum concentration of Cabazitaxel can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Cabazitaxel can be increased when combined with Primidone.
ProbenecidThe serum concentration of Cabazitaxel can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Procarbazine.
ProgesteroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Cabazitaxel.
PromethazineThe serum concentration of Cabazitaxel can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Cabazitaxel can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Cabazitaxel can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Cabazitaxel can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cabazitaxel.
Purine RibosideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Purine Riboside.
PuromycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Puromycin.
QuercetinThe serum concentration of Cabazitaxel can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Cabazitaxel.
QuinacrineThe serum concentration of Cabazitaxel can be increased when it is combined with Quinacrine.
QuinacrineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Quinacrine.
QuinidineThe serum concentration of Cabazitaxel can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Cabazitaxel can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Cabazitaxel can be decreased when combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rabies vaccine.
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Radium Ra 223 Dichloride.
RaltitrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Raltitrexed.
RamucirumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ramucirumab.
RanibizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranibizumab.
RanitidineThe serum concentration of Cabazitaxel can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cabazitaxel.
RanpirnaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranpirnase.
ReboxetineThe serum concentration of Cabazitaxel can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Cabazitaxel can be increased when it is combined with Regorafenib.
RegorafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Regorafenib.
ReserpineThe serum concentration of Cabazitaxel can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Cabazitaxel.
ResveratrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.
Rhodamine 6GThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rhodamine 6G.
RifabutinThe metabolism of Cabazitaxel can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Cabazitaxel can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cabazitaxel.
RifapentineThe metabolism of Cabazitaxel can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cabazitaxel.
RilpivirineThe serum concentration of Cabazitaxel can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Cabazitaxel.
RitonavirThe serum concentration of Cabazitaxel can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Cabazitaxel.
RituximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cabazitaxel.
RoflumilastRoflumilast may increase the immunosuppressive activities of Cabazitaxel.
RolapitantThe serum concentration of Cabazitaxel can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Cabazitaxel.
RomiplostimThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Romiplostim.
RoquinimexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Roquinimex.
RosiglitazoneThe metabolism of Cabazitaxel can be decreased when combined with Rosiglitazone.
RubitecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rubitecan.
RuxolitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Cabazitaxel.
SaquinavirThe serum concentration of Cabazitaxel can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cabazitaxel.
SatraplatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Satraplatin.
ScopolamineThe serum concentration of Cabazitaxel can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Cabazitaxel can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Cabazitaxel can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cabazitaxel.
SeliciclibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seliciclib.
SemaxanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Semaxanib.
SeocalcitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seocalcitol.
SertralineThe serum concentration of Cabazitaxel can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Cabazitaxel can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.
SiltuximabThe serum concentration of Cabazitaxel can be decreased when it is combined with Siltuximab.
SiltuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Siltuximab.
SimeprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Cabazitaxel can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cabazitaxel.
SirolimusThe serum concentration of Cabazitaxel can be decreased when it is combined with Sirolimus.
SirolimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cabazitaxel.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cabazitaxel.
SonidegibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sonidegib.
SorafenibThe serum concentration of Cabazitaxel can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Cabazitaxel.
Sparfosic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfosic acid.
SparsomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparsomycin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cabazitaxel.
SpironolactoneThe serum concentration of Cabazitaxel can be increased when it is combined with Spironolactone.
squalamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with squalamine.
SRT501The risk or severity of adverse effects can be increased when Cabazitaxel is combined with SRT501.
St. John's WortThe serum concentration of Cabazitaxel can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Cabazitaxel can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Cabazitaxel can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Cabazitaxel can be decreased when it is combined with Streptozocin.
StreptozocinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Streptozocin.
SulfamethoxazoleThe metabolism of Cabazitaxel can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Cabazitaxel can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Cabazitaxel can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulindac.
SumatriptanThe serum concentration of Cabazitaxel can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Cabazitaxel can be increased when it is combined with Sunitinib.
SunitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sunitinib.
SuraminThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Suramin.
SwainsonineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Swainsonine.
TacrineThe serum concentration of Cabazitaxel can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cabazitaxel.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Cabazitaxel.
TamoxifenThe serum concentration of Cabazitaxel can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Cabazitaxel.
Taurocholic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cabazitaxel.
TegafurThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tegafur.
TelaprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Cabazitaxel can be increased when it is combined with Telmisartan.
TemafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temafloxacin.
TemozolomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temozolomide.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Cabazitaxel.
TeniposideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Teniposide.
TerazosinThe serum concentration of Cabazitaxel can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Cabazitaxel can be increased when it is combined with Terfenadine.
TeriflunomideThe metabolism of Cabazitaxel can be decreased when combined with Teriflunomide.
TesmilifeneThe serum concentration of Cabazitaxel can be decreased when it is combined with Tesmilifene.
TestolactoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Testolactone.
TestosteroneThe serum concentration of Cabazitaxel can be increased when it is combined with Testosterone.
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tetrathiomolybdate.
TezacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tezacitabine.
ThalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thalidomide.
ThiotepaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thiotepa.
ThymalfasinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thymalfasin.
TiboloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cabazitaxel.
TiclopidineThe metabolism of Cabazitaxel can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Cabazitaxel.
TioguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tioguanine.
TipifarnibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tipifarnib.
TirapazamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tirapazamine.
TocilizumabThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.
TofacitinibCabazitaxel may increase the immunosuppressive activities of Tofacitinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cabazitaxel.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cabazitaxel.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Cabazitaxel.
TositumomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tositumomab.
TrabectedinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trabectedin.
TrametinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trametinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Cabazitaxel.
TrastuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trastuzumab.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Cabazitaxel.
TrazodoneThe serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone.
TretinoinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tretinoin.
TrifluoperazineThe serum concentration of Cabazitaxel can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Cabazitaxel can be increased when it is combined with Triflupromazine.
TrifluridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trifluridine.
TrilostaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trilostane.
TrimethoprimThe serum concentration of Cabazitaxel can be decreased when it is combined with Trimethoprim.
TrimetrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trimetrexate.
TrimipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Trimipramine.
TriptorelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptorelin.
TroleandomycinThe serum concentration of Cabazitaxel can be increased when it is combined with Troleandomycin.
TrovafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trovafloxacin.
TroxacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Troxacitabine.
TTNPBThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with TTNPB.
TubercidinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tubercidin.
UbenimexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cabazitaxel.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cabazitaxel.
Uracil mustardThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Uracil mustard.
ValrubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Valrubicin.
VandetanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vandetanib.
VapreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vapreotide.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cabazitaxel.
VeliparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Veliparib.
VemurafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vemurafenib.
VenlafaxineThe metabolism of Cabazitaxel can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Cabazitaxel.
VerapamilThe metabolism of Cabazitaxel can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cabazitaxel.
VerteporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin.
VinblastineThe serum concentration of Cabazitaxel can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Cabazitaxel.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cabazitaxel.
VincristineThe serum concentration of Cabazitaxel can be decreased when it is combined with Vincristine.
VindesineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vindesine.
VinorelbineThe serum concentration of Cabazitaxel can be increased when it is combined with Vinorelbine.
VinorelbineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Cabazitaxel.
Vitamin AThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vitamin A.
VoriconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Voriconazole.
VorinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vorinostat.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Cabazitaxel.
ZimelidineThe serum concentration of Cabazitaxel can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA4A
Uniprot ID:
P68366
Molecular Weight:
49923.995 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. JEVTANA [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. JEVTANA [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. JEVTANA [Link]
Comments
comments powered by Disqus
Drug created on September 14, 2010 10:21 / Updated on September 28, 2016 02:27